Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main...
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Merck to further study Keytruda in prostate cancer after early successMerck & Co Inc said on Thursday it was launching three late-stage studies for it...
Weiterlesen »
Merck, Pfizer drug combo extends kidney cancer survival: studyA combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's ...
Weiterlesen »
Merck to further study Keytruda in prostate cancer after early successMerck & Co Inc said on Thursday it was launching three late-stage studies for it...
Weiterlesen »
Merck, Pfizer drug combo extends kidney cancer survival: studyA combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's ...
Weiterlesen »
Pfizer-Lilly drug shown to help reduce back pain in late-stage trialA non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded i...
Weiterlesen »
All breast cancer patients should get genetic testing, surgeons sayGenetic testing should be made available for all patients diagnosed with breast cancer, according to new guidelines from the American Society of Breast Surgeons
Weiterlesen »
Breast surgeons say all breast cancer patients should be offered genetic testingCurrent guidelines are too restrictive and may be missing people with mutations that could affect prevention and treatment, the surgeons group says.
Weiterlesen »
Racial disparities in US cancer deaths are shrinking, study findsHistorical disparities between black and white cancer patients in the United States are receding, a new study finds. Among men, the overall cancer death rate was 47% higher for blacks than for whites in 1990, but that difference dropped to 19% in 2016, and the disparity has been nearly eliminated in men younger than 50.
Weiterlesen »
Immunotherapies could change kidney cancer care, studies suggestTwo studies showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an immunotherapy -- one study used pembrolizumab, or Keytruda, and the other used avelumab, or Bavencio.
Weiterlesen »